UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000006755
Receipt number R000007930
Scientific Title A dandomized phase ll study consisting S-1 + CDDP (SP) and Capecitabin + CDDP (XP) for adversed/metastatic gastric cancer with mesurable lesions and HER2 negative tumor (HERBIS-4A) (OGSG 1105)
Date of disclosure of the study information 2011/11/21
Last modified on 2022/09/25 21:27:24

No. Disposal Last modified on Item of update
1 Insert 2011/11/21 18:46:16
2 Update 2011/11/26 20:00:20 Public title
Public title
Acronym
Acronym
3 Update 2011/11/26 20:02:10 Last follow-up date
4 Update 2011/11/26 20:15:35 Last name of lead principal investigator
Last name of lead principal investigator
Organization
Organization
Division name
Division name
Address
Address
TEL
5 Update 2011/11/26 21:05:12 Classification by specialty
Narrative objectives1
Narrative objectives1
Primary outcomes
Primary outcomes
Key secondary outcomes
Key secondary outcomes
6 Update 2011/11/27 00:17:07 Interventions/Control_1
Interventions/Control_1
Interventions/Control_2
Interventions/Control_2
Key inclusion criteria
Key inclusion criteria
7 Update 2011/11/29 00:05:22 Key secondary outcomes
8 Update 2011/11/30 19:25:25 Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
9 Update 2012/06/24 22:16:45 Recruitment status
10 Update 2012/06/24 22:20:33 Organization
Organization
Division name
Division name
Address
Address
TEL
Organization
Organization
Division name
Division name
Address
Address
TEL
Email
Organization1
Address1
Tel1
Email1
11 Update 2012/06/24 22:29:13 Public title
Public title
Acronym
Acronym
12 Update 2013/05/22 20:19:51 Anticipated trial start date
Last follow-up date
13 Update 2014/11/23 19:06:11 Last follow-up date
14 Update 2014/11/23 19:16:18 Email
Email
Institutions
15 Update 2015/05/28 23:16:29 Email
Email
Institutions
16 Update 2015/11/23 23:24:08 Institutions
17 Update 2016/05/23 21:36:12 Name of primary person or sponsor
Organization
Institutions
18 Update 2016/06/30 23:21:55 Recruitment status
Last follow-up date
19 Update 2018/04/30 23:38:56 Email
Email
20 Update 2018/05/10 20:29:14 Email
Email
21 Update 2018/08/01 22:07:20 UMIN ID1
22 Update 2018/08/01 22:09:23 Name of person sending information
Name of person sending information
Organization
Organization
Division name
Division name
Address
Address
TEL
Email
23 Update 2019/02/20 23:10:45 Recruitment status
Date analysis concluded
24 Update 2020/01/05 15:09:47 Date of IRB
25 Update 2020/01/05 16:08:46 URL releasing protocol
Publication of results
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results
Results date posted
Date of the first journal publication of results
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
26 Update 2020/01/05 16:36:07 Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
27 Update 2020/01/22 22:05:39 Date of IRB
28 Update 2022/09/25 21:27:25 Date of the first journal publication of results